Submitted by webmaster on April 10, 2016
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).
October 1, 2015 to December 1, 2017
Add new comment